LeonaBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
LeonaBio, Inc. (LONA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-08-14
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
- LeonaBio, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2021 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-05-07 | |||
| 2025-09-30 | 0.00% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2025-05-09 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-31 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2024-05-15 | |||
| 2023-12-31 | 0.00% 10-K · filed 2024-02-22 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | 0.00% 10-K · filed 2023-03-23 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | 0.00% 10-K · filed 2022-03-28 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 0.00% 10-K · filed 2021-03-25 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2020-11-12 | |||
| 2019-12-31 | 0.00% 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |